ASX Announcements
Application for quotation of securities - TLX
Appendix 2A (Application for Quotation of Securities)
- Jan 31, 2025
- 6 pages
Notification regarding unquoted securities - TLX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities)
- Jan 31, 2025
- 6 pages
Application for quotation of securities - TLX
Appendix 2A (Application for Quotation of Securities)
- Jan 31, 2025
- 6 pages
December 2024
The stocks that did the most damage in 2024 – and the ones that ruled
One fintech darling has more than tripled in the past 12 months, but the same can’t be said for lithium stocks on the front line of the EV slowdown.
- Joshua Peach and Joanne Tran
October 2024
Telix boss says Australia ‘horrible’ at getting drugs to patients
Christian Behrenbruch, the founder of ASX biotech giant Telix, says Australia has a “horrible” track record getting drugs to patients and lags rest of the world.
- Michael Smith
Telix revives US listing plans, says sales to double on new drugs
The cancer treatment giant wants to sell shares to investors and staff in North America as it eyes growth in the region.
- Michael Smith
September 2024
Telix on $1b spending spree to build US radiopharmacy network
The biotech is investing heavily in global networks that will enable it to control the supply and distribution of nuclear medicines used to treat cancer.
- Michael Smith
The five pharma stocks exciting investors
Risky but with rewards, Australian pharmaceutical companies developing treatments for rare diseases are competing for investor attention.
- Michael Smith
July 2024
Telix upsizes convertibles deal to $650m; delta block clears at $18.70
The pharmaceuticals company joins Xero and New Hope, which raised $1.27 billion and $300 million respectively in June via convertibles.
- Sarah Thompson, Kanika Sood and Emma Rapaport
JPMorgan shops $226m delta placement block for Telix notes deal
Terms sent to potential investors show Telix shares were being offered under a variable price book build at $18.60 a share to $19.60.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Telix shares hit new high on upgraded revenue forecast
The biotech’s shares double in value this year due to strong sales in the United States for its prostate cancer imaging product.
- Michael Smith
The ’10-bagger’ stocks that helped push the ASX above 8000
Two blockbuster biotech winners and beneficiaries of investment in the energy transition helped create wealth for savvy investors as shares topped 8000 points.
- Tom Richardson
June 2024
Aussie high-flyer’s wings clipped by US investors
Red-hot biotech Telix got a shock when US investors wanted a chunky discount to buy stock. So it’s walking away looking silly, but with its pride intact.
- Anthony Macdonald
Telix pulls $300m Nasdaq IPO as investors demand deep discount
The cancer treatment hopeful had announced plans to list in New York only last week as it searched for more capital. On Friday, it withdrew from the initial public offering.
- Kylar Loussikian
Telix greenlights $300m Nasdaq listing in search for deep pockets
It is the second ASX-listed growth stock to flag intentions to list in New York, with Life360, the developer of family social media apps, to debut overnight.
- Joshua Peach
April 2024
Alium Capital preps first new fund in seven years
The Sydney investor is targeting wealth groups and superannuation funds for its new private and public equity fund.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Why picking ASX biotechs is mostly for the crazy brave
It’s a space with a reputation for rollercoaster returns and outlandish sales pitches, but some investors get lucky.
- Tom Richardson
January 2024
- Opinion
- Chanticleer
Why $3b Aussie darling Telix needs to grow wings
If Telix wants to truly mix it with the big players, it needs to be closer to those that can fund it.
- Anthony Macdonald
June 2023
Aussie nuclear medicine firm breaks into EU amid huge growth
Melbourne-based Telix has opened a $21 million factory in Belgium which allows it to deliver to Europe, likely adding another leg to its already breakneck growth.
- Hans van Leeuwen
October 2022
The cash clues that suggest Dreamworld owner is wildly undervalued
Pengana’s James McDonald is tipping into Aussie names Telix and Opthea, potash producer K+S, and the valuation case for Ardent at 70¢.
- Emma Rapaport
August 2022
China’s Grand Decade drops $73m Telix stake, JPM seeks buyers
JPMorgan’s equities desk is seeking buyers about a 3 per cent stake in ASX-listed Telix Pharmaceuticals on Thursday evening.
- Anthony Macdonald, Sarah Thompson and Kanika Sood
Tech rally gathers pace, Block, Atlassian earnings ahead
Shares closed flat as a tech sector rally was offset by falls among the miners. Afterpay-owner Block will report its June-quarter results on Friday morning.
- Tom Richardson
Fund managers back market darling Telix Pharmaceuticals
Healthcare analysts and Australian equities managers have profited from buying fast-rising oncology business Telix, after it unveiled strong sales.
- Tom Richardson